She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...